Aside from the well-known amyloid beta and tau pathologies found in Alzheimer's disease (AD), neuroinflammation is a well-established aspect described in humans and animal models of the disease. Inflammatory perturbations are evident not only in neurons, but also in non-neuronal cells and cytokines in the AD brain. Although the amyloid hypothesis implicates amyloid beta (Aβ) as the prime initiator of the AD, brain inflammation in AD has a complex relationship between Aβ and tau. Using our work with the 5-lipoxygenase protein as an example, we suggest that at least in the case of AD, there is an interdependent and not necessarily hierarchical pathological relationship between Aβ, tau and inflammation.
Introduction
Alzheimer's disease (AD) is the most common neurodegenerative dementia. Clinically, AD is characterized by progressive, irreversible memory loss and global cognitive decline. In the vast majority of cases, symptoms typically manifest late in life, and by the age of 85 nearly half of all patients are thought to suffer from some form of the disease. Current estimates place the prevalence of AD at over 5 million in the United States alone, projected to rise to over 15 million by the year 2050. Financially, the economic burden of AD is thought to be in excess of $200 billion USD, and is expected to rise dramatically given an aging population worldwide [1] . AD is characterized by accumulation of amyloid β (Aβ) plaques and neurofibrillary tangles (NFT) composed of hyperphosphorylated tau protein in the brain.
Investigation of these two molecules in the past three decades has revealed that abnormalities of their metabolism and subsequent dysfunction are crucial in the development of not only the molecular brain pathology of AD but also its behavioral sequelae (for a review see [2] ). Aβ is formed by the sequential cleavage of the Aβ precursor protein, APP, by β-and γ-secretases.
While it was originally believed that plaques were the most pathologic conformations of Aβ peptides, more recent evidence suggests that low-n oligomers, precursors to β-rich fibrillar structures, are responsible for dysruption in the synaptic milieu and ultimately the evolution of AD cognitive symptomatology [3] . The microtubule-associated tau protein is thought to be crucial for maintenance of axonal ultrastructure. In AD, hyperphosphorylation of tau reduces affinity for microtubules and causes aggregation, leading to insoluble intraneuronal tangles, which are believed to be neurotoxic inducing axonal damage and altered synaptic integrity and ultimately cognitive impairments [4] . Since there exist rare familial forms of AD in which mutations in APP and secretase proteins are associated with early onset and accelerated cognitive decline, and that recent evidence of APP mutations that lower AD risk, it is generally thought that Aβ rather than tau plays an initiating role in AD pathophysiology.
Supporting this hypothesis are some animal data which show that tau pathology is highly dependent on the accumulation of Aβ [5, 6] [10] [11] [12] . As an illustration of this observation, Permanne and colleagues found that administration of peptides that interfere with β-sheet structure of Aβ peptides result in both reduction of plaque burden as well as microgliosis in mice [13] . Additionally, while early in the course of disease, microglia assume an activated-type morphology, at later stages, microglia assume more of a dystrophic phenotype [14] . Microglia can also be modulated by tau, as tau oligomers and fibrils have been shown to shift them towards an activated phenotype [15] . In turn, microglial activation has been shown to lead to phosphorylation of tau and tau aggregation [16, 17] . Overall, brain microgliosis has been demonstrated to follow the progression of AD histopathology -degree of microgliosis predicts brain burden of NFTs and has even reported to precede significant amyloid plaque deposition in transgenic animals [18, 19] .
As with microgliosis, astrocytosis precedes neuronal loss in transgenic animals as shown by Wright and colleagues [19] . Astrocytosis correlates with cognitive decline in AD, but an unclear association exists between astrocytosis
and Aβ plaque accumulation. Astrocytes have also been reported to produce Aβ at low levels [19, 20] . Although the mechanism remains elusive, Aβ peptides can induce astrocytic and neuronal calcium dysregulation and subsequent neurodegeneration [21] .
In primary neurons at least, Aβ-induced tau phosphorylation and caspase-mediated cell death require co-culture with astrocytes [22] , suggesting astrocytes play a crucial role in mediating downstream Aβ neurotoxicity.
A direct consequence of microglial and astrocytic activation, many pro-inflammatory cytokines have been described to be elevated in the AD brain and cerebrospinal fluid, including IL-1β, TNFα, and IFNγ (for a review, see [23] ). These cytokines appear to be generated as a result of elevated Aβ levels in vivo, and independently increase production of Aβ pathology. Similarly, neuronal exposure to cytokines such as IL-1β leads to amplification of tau phosphorylation [24] .
Thus, taken as whole, current data indicates that inflammation is present when AD plaque and tangle deposition occur, and that AD neuropathology promotes a pro-inflammatory state. Since Aβ-induced neuronal dysfunction is currently thought to initiate the AD phenotype, the logical assumption would be that it too would play an initiatory role in the proinflammatory brain state in AD. However, we believe that inflammation in AD may be more complex than this understanding. Below, we describe how our work with 5-lipoxygenase (5LO) challenges this notion.
5-Lipoxygenase: a modulator the Alzheimer's disease phenotype
The 5-lipoxygenase protein is so named because it inserts oxygen into Carbon 5 position of fatty acids such as arachidonic acid. 5LO is well known for its critical role in leukotrienes production. Leukotrienes are important mediators of inflammation, atherosclerosis, and have been shown to be involved in cancer biology [25, 26] . 5LO protein is widely expressed in the central nervous system, and is found in neurons as well as glia [27] .
5LO is richly expressed in human and murine hippocampus and cortex, and increases as a function of aging [28] . 5LO immunoreactivity is particularly robust and associated with Aβ plaques and NFTs in both AD patients and transgenic AD rodent models [29] . We utilized We corroborated these findings of Aβ pathology in the 3xTg mouse and found that additionally, 5LO also acts on tau metabolism. Genetic unavailability of 5LO or its overexpression correlates directly with increased and diminished, respectively, tau phosphorylation, insoluble tau aggregation and NFT development [35, 36] . We have shown that this aspect of 5LO is mediated by the cyclin-dependent kinase 5 (cdk5) [37] .
Since 5LO affected both aspects of AD pathology, we have explored whether tau is modulated by 5LO action on Aβ or whether 5LO action on tau is Aβ-independent. Under the inhibition of γ-secretase and reduced Aβ levels, in vitro hyperphosphorylation of tau caused by 5LO overexpression is unhindered [38] . Taken together these data support the hypothesis that 5LO independently modulates both Aβ and tau metabolism in AD. They provide a strong biological basis for the "dual pathway" model of the disease, in which the two major players (Aβ and tau) can act independently from each other. Following the trends of AD pathology, 5LO inhibition or knockout is also associated with improved markers of synaptic integrity as well as rescue of AD-associated memory deficits [31, 36] . 
5LO in the in ammationexacerbated AD phenotype
Leukotriene metabolites promote immune cell chemotaxis and initiates signal transduction through G protein-couple receptors [25] .
We had preliminarily investigated the role of 5LO pathway inhibition on an inflammatory phenotype indirectly. In the Tg2576 model, inhibition of 5LO activity results in reduced microgliosis and astrocytosis [39] . However, given that 5LO inhibition results in lower Aβ production, it was unclear to us whether this cytokines IL-1β and IFNγ in 3xTg animals [40] .
In those animals lacking 5LO, no memory deficits or γ-secretase elevation were observed, and brain Aβ levels were reduced. This was unsurprising given our previous knowledge of 5LO knockout in these animals. LPS-induced microgliosis, astrocytosis and cytokine were also reduced to baseline levels in 5LO knockout animals -this observation was also expected as 5LO metabolites are potent inflammatory
mediators.
An unexpected finding, however, was the persistence of tau phosphorylation. We assessed several different epitopes of tau, including those which indicated early and late stage phosphorylation. In our previous work, we found that 5LO inhibition prevented both early and late-stage phosphorylation, but LPS-stimulation still was able to induce early-stage tau phosphorylation regardless of 5LO status. When we assayed several tau kinases previously shown to be dysregulated in human AD brains, we found that the cdk5 coactivator p25 was elevated as a result of LPS administration and was unchanged by 5LO availability.
To summarize (Fig. 1) , in our system, one with reduced Aβ levels and neuroinflammation, we found that LPS was still able to induce tau phosphorylation through a cdk5-associated mechanism. This finding suggests that 
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